# Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer

> **NCT03657641** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Southern California** · enrollment: 75 (estimated)

## Conditions studied

- Colorectal Cancer
- Colorectal Cancer Metastatic

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Regorafenib

## Key facts

- **NCT ID:** NCT03657641
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-06-21
- **Primary completion:** 2023-02-27
- **Final completion:** 2026-06-21
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2025-07-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03657641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03657641, "Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03657641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*